Spectral domain optical coherence tomography imaging of dry age-related macular degeneration.

Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 NW 17th St., Miami, FL 33136 , USA.
Ophthalmic Surgery Lasers and Imaging (Impact Factor: 1.32). 11/2010; 41 Suppl:S6-S14. DOI: 10.3928/15428877-20101031-19
Source: PubMed

ABSTRACT Spectral domain optical coherence tomography is a useful new technology for imaging and measuring geographic atrophy (GA) and drusen, the hallmarks of dry age-related macular degeneration (AMD). The advantage of using this novel technique over other imaging modalities for dry AMD is that the same scan pattern can be used to image both drusen and GA while obtaining reproducible, quantitative data on both the area of GA and the morphologic features of drusen. Moreover, this strategy enables the clinician to follow the disease as it progresses from drusen to both GA and choroidal neovascularization. No other imaging modality is able to quantitatively assess all forms of AMD. This unique feature of spectral domain optical coherence tomography makes it the ideal imaging modality for clinical trials designed to assess new drugs for the treatment of dry AMD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: To develop a parameter that can assess the relative rate of progression of geographic atrophy (GA) based on the hypothesis that noncircular configuration of the atrophic lesion may be a risk factor for enlargement. Cohort study. Digitized color photographs of 593 eyes with GA from the Age-Related Eye Disease Study (AREDS). A novel parameter called the "Geographic Atrophy Circularity Index" (GACI) was developed on the basis of area and perimeter measurements to categorize the irregularity of the shape of GA. The GACI ranges from 0.0 to 1.0 and is categorized into 3 groups: 0.25 (very irregular), 0.25 to <0.75 (partly irregular), and ≥0.75 (circular). Growth rate of GA. The mean growth rate in the 3 categories was 0.40 (±0.18), 0.36 (±0.30), and 0.21 (±0.22) mm/year, respectively (P < 0.001). By adjusting for known confounders, baseline area, duration of GA, and configuration, GACI categories were significantly associated with increased growth rate of GA (P < 0.001). The GACI was associated with the progression rate of GA and may be a useful measure for clinical trial eligibility. The association also suggests that enlargement of GA may be related to the extent of the junctional zone of damaged retinal pigment epithelium, which increases with noncircularity for a given GA area. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
    Ophthalmology 10/2013; · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluates the potential of serum pro-inflammatory cytokines as AMD biomarkers.
    Albrecht von Graæes Archiv für Ophthalmologie 07/2014; · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Age-related macular degeneration (AMD) is the leading cause of vision loss in those over the age of 50 years in the developed countries. The number is expected to increase by ∼1.5 fold over the next ten years due to an increase in ageing population. One of the main measures of AMD severity is the analysis of drusen, pigmentary abnormalities, geographic atrophy (GA) and choroidal neovascularization (CNV) from imaging based on colour fundus photograph, optical coherence tomography (OCT) and other imaging modalities. Each of these imaging modalities has strengths and weaknesses for extracting individual AMD pathology and different imaging techniques are used in combination for capturing and/or quantification of different pathologies. Current dry AMD treatments cannot cure or reverse vision loss. However, the Age-Related Eye Disease Study (AREDS) showed that specific anti-oxidant vitamin supplementation reduces the risk of progression from intermediate stages (defined as the presence of either many medium-sized drusen or one or more large drusen) to late AMD which allows for preventative strategies in properly identified patients. Thus identification of people with early stage AMD is important to design and implement preventative strategies for late AMD, and determine their cost-effectiveness. A mass screening facility with teleophthalmology or telemedicine in combination with computer-aided analysis for large rural-based communities may identify more individuals suitable for early stage AMD prevention. In this review, we discuss different imaging modalities that are currently being considered or used for screening AMD. In addition, we look into various automated and semi-automated computer-aided grading systems and related retinal image analysis techniques for drusen, geographic atrophy and choroidal neovascularization detection and/or quantification for measurement of AMD severity using these imaging modalities. We also review the existing telemedicine studies which include diagnosis and management of AMD, and how automated disease grading could benefit telemedicine. As there is no treatment for dry AMD and only early intervention can prevent the late AMD, we emphasize mass screening through a telemedicine platform to enable early detection of AMD. We also provide a comparative study between the imaging modalities and identify potential study areas for further improvement and future research direction in automated AMD grading and screening.
    Progress in Retinal and Eye Research 11/2013; · 9.90 Impact Factor

Full-text (2 Sources)

Available from
Jun 3, 2014